000			02054 a2200529 4500
005			20250513193650.0
264		0	_c19991025
008			199910s 0 0 eng d
022			_a0022-2143
024	7		_a10.1016/s0022-2143(99)90155-5 _2doi
040			_aNLM _beng _cNLM
100	1		_aPeerschke, E I
245	0	0	_aMaintenance of GPIIb-IIIa avidity supporting "irreversible" fibrinogen binding is energy-dependent. _h[electronic resource]
260			_bThe Journal of laboratory and clinical medicine _cOct 1999
300			_a398-404 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, U.S. Gov't, P.H.S.
650	0	4	_aAdenosine Diphosphate _xpharmacology
650	0	4	_aAndrostadienes _xpharmacology
650	0	4	_aAnti-Bacterial Agents _xpharmacology
650	0	4	_aAntibodies, Monoclonal
650	0	4	_aAntimetabolites _xpharmacology
650	0	4	_aAntimycin A _xpharmacology
650	0	4	_aBenzoquinones
650	0	4	_aBlood Platelets _xenzymology
650	0	4	_aDeoxyglucose _xpharmacology
650	0	4	_aDimethyl Sulfoxide _xpharmacology
650	0	4	_aEnergy Metabolism _xdrug effects
650	0	4	_aEnzyme Inhibitors _xpharmacology
650	0	4	_aEnzyme-Linked Immunosorbent Assay
650	0	4	_aExcipients _xpharmacology
650	0	4	_aFibrinogen _xmetabolism
650	0	4	_aHumans
650	0	4	_aLactams, Macrocyclic
650	0	4	_aPhosphorylation
650	0	4	_aPlatelet Aggregation _xdrug effects
650	0	4	_aPlatelet Glycoprotein GPIIb-IIIa Complex _xmetabolism
650	0	4	_aPolylysine
650	0	4	_aProtein Binding _xdrug effects
650	0	4	_aProtein-Tyrosine Kinases _xantagonists & inhibitors
650	0	4	_aQuinones _xpharmacology
650	0	4	_aRifabutin _xanalogs & derivatives
650	0	4	_aSignal Transduction _xphysiology
650	0	4	_aTyrosine _xmetabolism
650	0	4	_aWortmannin
773	0		_tThe Journal of laboratory and clinical medicine _gvol. 134 _gno. 4 _gp. 398-404
856	4	0	_uhttps://doi.org/10.1016/s0022-2143(99)90155-5 _zAvailable from publisher's website
999			_c10478089 _d10478089